Mn-SOD与抗癌胚抗原单链抗体基因的融合及高效表达

将Ｍｎ－ＳＯＤ与抗癌胚抗原（ＣＥＡ）单链抗体基因（Ｓｃ－Ｆｖ ｇｅｎｅ）融合,重组到含Ｔ７启动子的表达载体ｐＥＴ－２２ｂ（＋）中,构建表达质粒ｐＥＴＭｎ－ＳＯＤ－ＳｃＦｖ,并转化大肠杆菌ＢＬ２１（ＤＥ３）,进行高效表达,表达物占菌体可溶性总蛋白的２４％。ＳＤＳ－ＰＡＧＥ和蛋白质和迹图谱显示表达物分子量为４５ｋＤ与融合基因编码蛋白质的理论值相符。该蛋白质在大肠杆菌中为泌型表达有利于纯化。ＲＩＡ测定表     

凝血酶激活的单链尿激酶型纤溶酶原激活剂的构建、表达、纯化和性质研究

用Ｋｕｎｋｅｌ突变法,将单链尿激酶型纤溶酶原激活剂（ｓｃｕ－ＰＡ）ｃＤＮＡ基因中编码Ｐｒｏ１５５—Ｌｙｓ１５８的片段定点突变,并将此突变的ｓｃｕ－ＰＡ（ｔｓｃｕ－ＰＡ）的ｃＤＮＡ克隆到表达载体ｐＣＭ－β－ｎｅｏ中,与ｐＣＭ－ｄｈｆｒ共转染ＣＨＯ／ＤＨＦＲ－细胞．获得的稳定表达株在无血清培养基中２４ｈ的表达量为６２０ＩＵ／１０６细胞．经锌离子螯合Ｓｅｐｈａｒｏｓｅ亲和层析得到ｔｓｃｕ－ＰＡ纯品．ＳＤＳ－ＰＡＧＥ显示ｔｓｃｕ－ＰＡ分子量为５３ｋＤ左右,与预期的结果相符．ｔｓｃｕ－ＰＡ是由凝血酶激活而不是由纤溶酶激活,但激活后也能转变为双链分子（ｔｃｕ－ＰＡ）．ｔｓｃｕ－ＰＡ仍保持了ｓｃｕ－ＰＡ的血纤维蛋白亲和性．酶动力学研究表明,激活后的ｔｓｃｕ－ＰＡ水解Ｓ２４４４的Ｋｍ和Ｋｃａｔ值与高分子量尿激酶（ＨＵＫ）相似．体外溶栓实验结果表明,ｔｓｃｕ－ＰＡ可以选择性地溶解富含凝血酶的血凝块,对贫凝血酶的血凝块作用不大     

文摘

000042抗结肠癌相关抗原单链抗体基因的构建和表达[中]/朱林霞…//生物工程学报.-2000,16(1).-82～85通过ＰＣＲ扩增和酶切分别得到抗结肠癌相关抗原抗体的重链可变区序列、轻链可变区序列及连接肽序列,将它们构建成为ＶＨ-ｌｉｎｋｅｒ-ＶＬ形式的单链抗体基因片段,并在大肠杆菌中进行表达。ＳＤＳ-ＰＡＧＥ分析结果表明,以ｐＣｏｍｂ3为载体,在大肠肝菌ＪＭ83中,ｓｃＦｖ未获得有效表达,而以ｐＥＴ-22ｂ( )为载体的ｓｃＦｖ在大肠杆菌ＢＬ21(ＤＥ3)中,30℃诱导培养获得了高效表达,表达水平占全菌蛋白的35.5%。(杨淑培)000043大肠杆菌原核…     

文摘

010 112绿色荧光蛋白与黄瓜花叶病毒运动蛋白融合基因的构建及在大肠杆菌中的表达 [中 ]/李睿… / /农业生物技术学报 .-2 0 0 1,9(1) .- 19～ 2 2采用重组 -ＰＣＲ方法 ,扩增获得绿色荧光蛋白 (ＧＦＰ)与黄瓜花叶病毒运动蛋白 (ＣＭＶＭＰ)融合基因 ,将其克隆到ｐＫＥＮ上 ,构建了该融合基因的原核表达载体 ｐＫＥＮＧ -Ｍ。ＳＤＳ -ＰＡＥＧ及免疫印迹分析显示 ,5 7ｋＤ的融合蛋白基因在大肠杆菌ＤＨ5ａ中正确表达。激光共聚焦显微镜分析表明 ,在 488ｎｍ光激发下 ,菌体呈亮绿色 ,表明融合蛋白保持绿色荧光特性。实验结果为进一步研究ＣＭ…     

免疫亲和层析法纯化单链尿激酶型纤溶酶原激活剂

尿激酶原 (Ｐｒｏ ｕｒｏｋｉｎａｓｅ ,ｐｒｏ ＵＫ) ,也称单链尿激酶型纤溶酶原激活剂 (Ｓｉｎｇｌｅ ｃｈａｉｎｕｒｏｋｉｎａｓｅ ｔｙｐｅｐｌａｓｍｉｎｏｇｅｎａｃｔｉｖａｔｏｒ,ｓｃｕ ＰＡ) ,与ｔ ＰＡ一样是第二代溶栓药物。给药时 ,保持无活性的酶原状态 ,只激活被纤维蛋白吸附的纤溶酶原 ,而对游离的纤溶酶原没有作用 ,即只在血栓表面才能活化转变为双链尿激酶 (Ｔｗｏ ｃｈａｉｎｕｒｏｋｉｎａｓｅ ｔｙｐｅｐｌａｓｍｉｎｏｇｅｎａｃｔｉｖａｔｏｒ,ｔｃｕ ＰＡ或ＵＫ) ,因而具有较高的特异性溶血栓作用[1 ] 。尿激酶原…     

u-PA/t-PA嵌合型纤溶酶原激活剂(ut-PA)的构建、表达、纯化和性质研究

将尿激酶原（ｐｒｏ－ＵＫ）ｃＤＮＡ和组织型纤溶酶原激活剂（ｔ－ＰＡ）Ａ链ｃＤＮＡ克隆到Ｍ１３ｍｐ１８中,经过二次寡核甘酸诱导的大片段定点删除和一次寡核苷酸诱导的多位点突变,得到ｕ－ＰＡ（Ｌｅｕ１４４－Ｇｌｙ４０８）／ｔ－ＰＡ（Ｓｅｒ１－Ｔｈｒ２６３）（ｕｔ－ＰＡ）融合基因．将ｕｔ－ＰＡ融合基因克隆到表达载体ｐＣＭ－βｎｅｏ中,与ｐＣＭ－ｄｈｆｒ共转染ＣＨＯ／ＤＨＦＲ－细胞,筛选稳定表达株．收集无血清表达上清,经苯甲脒柱纯化得到ｕｔ－ＰＡ纯品,ＳＤＳ－ＰＡＧＥ和纤维蛋白自显影显示ｕｔ－ＰＡ有两种分子量形式,分子量分别为６８ｋＤ和６１ｋＤ．纤维蛋白亲和性试验表明,ＬＵＫ（低分子量尿激酶）对纤维蛋白没有亲和性,而含有ＬＵＫ的ｕｔ－ＰＡ则对纤维蛋白表现出很强的亲和性,但ｕｔ－ＰＡ的亲和性略低于亲本ｔ－ＰＡ．     

鼠源抗HFRSV衣壳蛋白McAbF3株单链抗体基因克隆构建及表达

为了获得原抗ＨＦＲＳＶ衣壳蛋白ＭｃＡｂＦ３＾１株轻链可变区基因,由连接肽体外连接获得单链抗体基因,在大肠杆菌中表达,从鼠源抗ＨＦＲＳＶ衣壳蛋白ＭｃＡｂＦ３株细胞中分离总ＲＮＡ,以ｏｌｉｇｏ（ｄＴ）１８为引物逆转录成ｃＤＮＡ,通过ＰＣＲ扩增出抗体的轻链（ＶＬ）和重链可变区（Ｖ１１）基因,由连接本外连接获得单链抗体（ＳｅＦｖ）基因。将此单链抗体（ＳｅＦｖ）基因插入原核表达载体ＰＥＴ２８ａ,经大肠杆菌（     

抗癌胚抗原单链抗体基因的构建及高效表达

采用重组ＰＣＲ技术将已获得的抗癌胚抗原鼠源单克隆抗体Ｅ７Ｂ１０重,轻链可变区基因经（Ｇｌｙ３Ｓｅｒ）３编码的寡核苷酸拼接成单链抗体基因,并在大肠杆菌中高效表达了单链抗体Ｃ端的融合蛋白,其表达量达到菌体总蛋白的２０％,ＳＤＳ－ＰＡＧＥ和Ｗｅｓｔｅｒｎ印迹图谱显示表达产物分子量为２７ｋＤ,与其基因编码蛋白的理论推算值相符。     

大肠杆菌表达质粒pSM43及pSM53的构建

利用已成功高表达ｅｒａ基因的质粒ｐＣＥ３１翻译起始码上游的序列,去构建大肠杆菌新的外源基因表达载体。先合成特定序列的单链脱氧寡核苷酸,以改进的实验程序插入ｐＪＬ６,其后再加上限制酶多克隆位点。所构建的ｐＳＭ４３和ｐＳＭ５３分别适合於不带翻译起码（ＡＴＧ）和带起始码的基因插入、表达非融合目的蛋白质之用。并已成功用於人肿瘤坏死因子、人骨形成蛋白、ＨＩＶ蛋白酶、Ｄｕｃｈｅｎｎｅ肌营养不良等ｃＤＮＡ基因的     

信号肽疏水性的提高促进青霉素G酰化酶分泌

设计和合成了一段具有连续１０仆亮氨酸强疏水核心的信号肽（ａｒｔｉｆｉｃｉａｌ ｓｉｇｎａｌ ｐｅｐｔｉｄｅ,ＡＳＰ）,由ＥｃｏＲＩ－ＫｐｎＩ位点融合到青霉素Ｇ酰化酶（ｐｅｎｉｃｉｌｌｉｎ Ｇａｃｙｌａｓｅ,ＰＡＣ）信号肽（ｗｉｌｄ ｔｙｐｅｓｉｇｎａｌ ｐｅｐｔｉｄｅ,ＷＴＳＰ）的－４Ｐｒｏ位点,分别构建了ＰＡＣ表达质粒：ｐＫＫｐａｃ△ＳＰ,ｐＫＫｐａｃＷＴＳＰ,ｐＫＫｐａｃＡＳＰ,ｐＥＴｐａｃ     

抗虫杀菌融合基因表达载体的构建及微束激光转化植物研究

将苏云金芽孢杆菌伴孢晶体蛋白的基因(Bacillus thuringiesis,简称Bt)通过甘氨酸接头(Gly4Ser)3与一种人工合成的抗菌肽(antimicrobial peptides,AMP)基因与相融合,编码一种新的杀虫,并具有抗菌的蛋白。把融合基因(NAMP-Bt)连接到原核表达载体pET-28a和植物表达载体pBI-121上,经过限制性酶切分析和PCR鉴定,结果表明含有融合基因的原核和真核重组表达质粒均已构建成功,并将该融合基因转入烟草,已获得抗性小植株。     

融合基因Mdc-hly的构建及原核表达

构建家蝇天蚕素-人溶菌酶(Mdc-hly)融合基因,实现Mdc-hly基因在大肠杆菌中的表达。通过RT-PCR分别扩增出家蝇天蚕素和人溶菌酶的成熟肽基因序列,再利用Gene-SOEing技术构建融合基因,将融合基因克隆至pET32a表达载体,转化E.coli BL21(DE3),经IPTG诱导得到高效表达,融合蛋白分子量约为38kD。Western blotting杂交证实了表达蛋白的抗原活性。成功构建了融合其因并进行了原核表达,为进一步的生物活性研究打下基础。     

抗人VEGF受体Ⅱ基因Ⅲ区单链抗体基因的构建和表达

采用RT-PCR技术从分泌抗人血管内皮生长因子受体Ⅱ（kinase insert domaincontaining receptor,KDR）基因Ⅲ区单克隆抗体Ycom1D3的杂交瘤细胞中克隆出VH和VL可变区基因,通过重叠延伸拼接（spliceoverlap extension）PCR方法在V_H和V_L基因之间引入柔性短肽（Gly₄Ser）₃,体外构建Ycom1D3单链抗体基因Ycom1D3-ScFv）,将其克隆至pAYZ表达载体,在大肠杆菌中表达。SDS-PAGE和Westernblot分析结果表明,Ycom1D3-ScFv在E.coli 16C9中获得表达,重组蛋白的相对分子量为30kD,与预期结果一致。表达产物主要以不溶性包涵体形式存在,经过溶解包涵体,TALON 金属亲合层析基质（TALON metal affinity resin）纯化和体外复性过程,获得了高纯度的单链抗体片段。流式细胞分析结果证实该单链抗体可与人脐静脉内皮细胞结合,保留了鼠源单抗与KDR抗原的特异性结合活性。抗KDRⅢ单链抗体基因Ycom1D3-ScFv的成功构建和功能性表达为靶向诊断治疗及进一步基因工程改造奠定了基础。     

H5N1亚型禽流感病毒血凝素蛋白单链抗体基因的克隆及表达

构建并表达H5N1亚型禽流感病毒血凝素蛋白单链抗体,为禽流感靶向治疗药物的研制制备靶向载体。从分泌血凝素单克隆抗体的杂交瘤细胞株中提取mRNA,采用RT-PCR法扩增出重链和轻链可变区基因,通过SOE-PCR法将重链和轻链通过Linker连接起来构建单链抗体基因,将获得的单链抗体基因装入原核表达载体pET28a(+)中,构建重组质粒并表达,以Western blot鉴定单链抗体的特异性。结果成功构建了单链抗体基因,全长714bp,经原核表达,所构建的单链抗体可与H5亚型禽流感病毒HA蛋白特异结合,为禽流感的靶向治疗奠定了基础。     

小鼠IL-27真核表达载体的构建及其在RAW264.7 细胞中的表达

目的:构建小鼠白介素27(Interleukin 27,IL-27)单链融合基因的真核表达载体并检验其在RAW264.7细胞中的表达情况。方法:提取小鼠脾细胞总RNA,通过RT-PCR扩增出小鼠EBI3和p28 c DNA。采用重叠延伸PCR(splicing by overlap extension PCR,SOE PCR)通过编码疏水性多肽接头(Gly4Ser)3的DNA序列连接小鼠EBI3和p28基因片段,构建小鼠IL-27单链融合基因(mouse single chain IL-27,msc IL-27),并将其克隆至pc DNA3.1(+)载体。通过酶切和测序鉴定阳性重组载体,将重组质粒pc DNA3.1-IL-27通过脂质体转染法转染小鼠巨噬细胞株RAW264.7,通过RT-PCR方法检测目的基因的表达。结果:测序分析表明,小鼠IL-27单链融合基因中EBI3、linker和p28的连接顺序、方向及碱基序列与预期相符。在转染后的RAW264.7细胞中检测到了小鼠IL-27 m RNA的表达。结论:成功构建了小鼠IL-27单链融合基因及其真核表达载体,并在RAW264.7细胞中实现表达,为进一步探讨IL-27的生物学功能奠定了基础。     

Gene cloning, bacterial expression, in vitro refolding, and characterization of a single-chain Fv antibody against PreS1(21-47) fragment of HBsAg

The murine monoclonal antibody 125E11 is an IgG which recognizes PreS1(21-47) fragment of large hepatitis B surface antigen. It has been successfully used for clinical detection of HBV virion in serum of hepatitis B patients. In present study, the genes of variable region in heavy chain (VH) and light chain (VL) of 125E11 have been cloned. Sequence analysis of cloned VH gene and VL gene showed that they had general characterization of immunoglobin variable region genes. According to Kabat classification, VH gene and VL gene belong to VH10 family, subgroup IIID and Vkappa family subgroup I, respectively. An expression vector of 125E11 single-chain Fv antibody fusion protein, in which VH and VL peptide were connected by a flexible linker (Gly(4)Ser)(3), was constructed. The scFv fusion protein was highly expressed in Escherichia coli mainly in inclusion body form. Using urea and pH gradient gel filtration method, the refolding of scFv was efficiently achieved. The refolding efficiency reached about 11% and 2.7 mg refolded scFv was obtained from 1L of culture. The binding activity and specificity of 125E11 scFv against PreS1(21-47)-containing antigen were also analyzed.     

抗人黑色素瘤单链抗体基因的克隆和分泌型表达

应用ＲＴ－ＰＣＲ技术从分泌抗人黑色素瘤单克隆抗体的杂交瘤细胞ＨＢ８７６０中克隆了抗体轻、重链可变区基因,然后用（Ｇｌｙ４Ｓｅｒ）３连接肽基因将ＶＨ、ＶＬ连接成ＳｃＦｖ基因,并进行了序列测定．计算机分析表明ＶＨ,ＶＬ均符合小鼠抗体可变区的特征,为功能性重排的抗体可变区基因．ＶＨ、ＶＬ、ｌｉｎｋｅｒ拼接正确．ＳｃＦｖ基因全长７２９ｂｐ,其中ＶＨ基因长３６０ｂｐ,编码１２０个氨基酸,ＶＬ基因长３２４ｂｐ,编码１０８个氨基酸．在噬菌粒表达载体ｐＣＡＮＴＡＢ５Ｅ中表达了可溶性的ＳｃＦｖ蛋白,表达产物经流式细胞仪检测可特异地与黑色素瘤细胞结合,不与肝癌、胃癌及良性黑痣细胞结合     

Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics

Interleukin-18 (IL-18) is a proinflammatory cytokine. This protein has a role in regulating immune responses and exhibits significant anti-tumor activities. Epidermal growth factor (EGF) is an important growth factor that plays a central role in the regulation of cell cycle and differentiation. It was proposed that a targeted delivery of IL-18 by generation of IL-18-EGF fusion protein might decrease adverse effects and result in enhancing cytotoxic and antitumor activities. In the present study, a fusion protein, consisting of EGFR binding domain fused to human IL-18 mature peptide via a linker peptide of (Gly(4)Ser) 3, was constructed and expressed in the insect cell line Sf9 using Bac-to-Bac baculovirus expression system. We showed that the purified recombinant fusion protein induced similar levels of IFN-gamma to that of native IL-18 protein in human PBMC in the presence of ConA. Furthermore, EGF receptor competitive test in human epithelial cancer A431 cell line showed that EGF-IL18 fusion protein can specifically bind with EGFR by competing with native EGF protein. These suggest that this rationally designed protein can be further developed as novel tumor therapeutics.     

抗人CD19单链抗体基因的构建、表达及功能测定

采用RT-PCR方法从分泌抗人类白细胞表面分化抗原CD19单克隆抗体的杂交瘤细胞中克隆出V_H和V_L可变区基因,再通过重叠延伸拼接（spliceoverlap extension）PCR方法在V_H和V_L可变区基因之间引入连接肽(Gly4Ser)3,体外构建抗人CD19单链抗体（抗CD19-ScFv）基因。将其克隆至表达载体PET28a并在大肠杆菌中表达。SDS-PAGE和Westernblot分析结果表明,抗CD19-ScFv在BL21（DE3）菌中获得表达,重组蛋白的相对分子量为27kD,表达产物以不溶性包涵体形式存在,经过溶解包涵体,镍柱亲和层析纯化和体外复性过程,获得了高纯度的单链抗体片段。流式细胞分析结果证实抗CD19ScFv可与人类白细胞表面的分化抗原CD19结合,保留了鼠源性单抗与CD19结合活性。抗人CD19-ScFv的构建与表达,为下一步针对B淋巴系统恶性肿瘤的靶向治疗奠定了基础。     

Enhancing granulocyte colony-stimulating factor expression in Pichia pastoris through fusion with human serum albumin

Protein fusion technology has emerged as one of the important strategies to increase the level of expression and half-life of therapeutic proteins in heterologous expression systems. Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic growth factor and is clinically used against neutropenia. Enhanced expression and stability of G-CSF were achieved in Pichia pastoris by the way of constructing a fusion protein with human serum albumin (HSA). The strategy involved polymerase chain reaction (PCR) amplification of fragments corresponding to codon-optimized G-CSF and domain 3 of HSA. Overlapping PCR was used to obtain the full-length fused gene (1,184?bp) with a 15-bp linker sequence comprising of 4 Gly and 1 Ser residues. Extracellular expression was carried out downstream of α-factor secretion signal sequence under the control of alcohol oxidase 1 promoter using pPICZαB. Excreted protein in the range of 110–380?mg?L^?1 was observed among the transformants. Effect of aeration and temperature was investigated in one of the transformants (35) overexpressing fusion protein and levels of G-CSF enhanced by 1.8-fold and 2.3-fold, respectively. Assay of biological activity indicated the fusion protein to retain similar cell proliferation activity as the commercial G-CSF preparation.